The command from Glasgow the first all over the world could tap a molecule which strengthens allergic reaction, and has successfully developed a biological agent which weakens symptoms of an anaphylactic shock.

This break can lead to huge reduction of quantity of lethal outcomes from an anaphylactic shock all over the world.
The anaphylaxis is strong allergic reaction - last stage of an allergic spectrum. Symptoms can include the general hyperemia, difficulties with breath, and can lead to heart attack and mors.

The widespread reasons of an anaphylaxis include foodstuff, such as a peanut, a wood nut, fish, molluscums, milk products and eggs. Also, stings of a bee or a wasp, natural latex (rubber), Penicillinum either any other preparation or an injection can be the reason.

Headed by doctor Alirio Melendez and professor Eddi I Pour, from University of Glasgow, the command has found out, that the new cytokine (an immune hormone) - IL-33 - plays the basic role in anaphylaxis development.

Doctor Melendez has told: "We have studied a number of patients which have tested an anaphylaxis during operation, and have found out, that at them very high level of the maintenance of molecule IL-33.

"IL-33 is rather new opening, and its role in an anaphylaxis (or any other pathology) is not up to the end clear yet.
"Our research has shown, that IL-33 plays the basic role in extremely enlarged inflammation which occurs in an anaphylactic shock, and has led us to understanding of, how it is necessary to interfere to reduce this influence.

"The anaphylactic shock causes large inflammatory reaction which is frequent so strong that breath is limited. In our research we have found out, that gravity of a shock is bound to molecule IL-33 which strengthens inflammatory reaction. It can lead to fatal narrowing of respiratory tracts and, eventually, to mors.

"Our research assumes, that patients with the strongest anaphylactic reaction have very high level of maintenance IL33.
"In general, without molecule IL33, allergic reaction would be less strong, that essentially would reduce risk of offensive of mors".

Results have been published in authoritative international magazine Proceedings of the National Association of Sciences («Materials of National Association of Sciences of the USA»).

The command successfully used mouse model to show, that blocking of molecule IL-33 reduces gravity of an attack.
Doctor Melendez has continued: "We used, a so-called, soluble receptor for the purpose of blocking of influence IL-33. By means of this soluble receptor - ST2 - the reaction usually caused IL-33 has been blocked.

"This approach has not stopped allergic reaction completely. It blocks the intensifying of reaction caused IL-33, but not allergic reaction.

"Now we investigate role IL-33 in an anaphylaxis and disorders similar to it, and we plan to continue these researches concerning an anaphylaxis caused by foodstuff, a poison and preparations.

"Our strategy now is application of a soluble receptor to IL-33 (sST2) to be convinced, that it is a potential biological agent which can be used against IL-33 during an anaphylactic shock.

"Time is necessary for working out of all instructions to confirm and begin clinical research of such biological agent.
"At the same time we study intercellular alarm mechanisms with which help IL-33 stimulates cellular reaction, for the purpose of definition of the mechanism of action of a new cytokine.

"However it is the important opening on a way of development of the best methods of treatment of this serious disease, and we are interested in working out of a suitable medicine for anaphylaxis treatment.

The research command is based at the Biomedical research centre at University of Glasgow, in unit of infections and immunology of faculty of medicine.

Lynn the Regent, the principal of anaphylactic campaign, has told: "Results of the research spent by doctor Melendezom and the professor I Pour at University of Glasgow, are encouraging. We would like, that this work developed further, until, while it does not become real advantage to people with an anaphylaxis, or those who is subject to risk of development of serious allergic reaction.

"Anaphylactic campaign completely supports such type of authoritative research and will be especially interested in seeing how its results can help people with an allergy, by granting of adequate allergic services".